Physician

Paul David Rocky Bilhartz, M.D., M.B.A.

According to 2025 Medicare claims, Paul Bilhartz, M.D., M.B.A. (NPI: 1376703108) practices interventional cardiology in the College Station-Bryan, TX market, with the plurality of this provider's patient population coming from Brazos, TX. This provider's primary affiliated billing organization is ROCKY D. BILHARTZ, M.D., P.A. (NPI: 1013214238; TIN: 275108176) and primary practice location at 77845-9998. Bilhartz is affiliated with the Baylor Scott & White Quality Alliance (ACO ID: A2542), participating under the MSSP model.

Bilhartz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 705 traditional Medicare patients, billed 3,690 HCPCS/CPT codes, and received $446,324 in Medicare payments. The top billing code was A9555 (Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries). Part D data shows 5,694 prescription claims across 727 beneficiaries totaling $1,244,356 in drug costs, led by Eliquis (Apixaban). 2016 DME data shows 30 claims. Open Payments data shows 72 records totaling $1,563. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $295,109 to $1,244,356. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	642	6,381	$470,044
2016	830	6,923	$484,522
2017	723	6,856	$568,981
2018	732	7,377	$597,503
2019	733	6,422	$681,487
2020	735	5,773	$556,840
2021	754	5,522	$527,791
2022	807	4,055	$468,070
2023	796	3,767	$444,538
2024	705	3,690	$446,324

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	301	2,399	$295,109
2016	337	2,617	$421,326
2017	369	3,044	$499,131
2018	424	3,665	$619,984
2019	494	4,275	$680,055
2020	541	4,634	$753,624
2021	592	4,905	$841,967
2022	632	5,283	$1,074,104
2023	688	5,719	$1,214,093
2024	727	5,694	$1,244,356

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	30	$1,947
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
A9555	Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries	124	126	$332
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	214	224	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	597	885	$87
93015	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician	128	128	$56
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	387	412	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	590	37,551	$692,593
Repatha Sureclick	Evolocumab	246	10,094	$188,776
Multaq	Dronedarone Hcl	33	2,714	$66,669
Entresto	Sacubitril/Valsartan	48	2,760	$59,528
Xarelto	Rivaroxaban	53	3,090	$56,441

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	72	$1,563	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul David Rocky Bilhartz, M.D., M.B.A.?

Tedicare shows public-source Medicare data for Paul David Rocky Bilhartz, M.D., M.B.A. (NPI 1376703108), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul David Rocky Bilhartz, M.D., M.B.A. have ACO affiliation data?

Paul David Rocky Bilhartz, M.D., M.B.A. is shown with ACO affiliation data for Baylor Scott & White Quality Alliance (MSSP, ACO ID A2542).

What billing organization is linked to Paul David Rocky Bilhartz, M.D., M.B.A.?

Paul David Rocky Bilhartz, M.D., M.B.A. is linked to ROCKY D. BILHARTZ, M.D., P.A. (billing NPI 1013214238) in the available physician profile data.

Does Paul David Rocky Bilhartz, M.D., M.B.A. have Open Payments data?

Paul David Rocky Bilhartz, M.D., M.B.A. has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.